Understanding the use of NIV in ALS: results of an international ALS specialist survey

Terry D. Heiman-Patterson, Merit E. Cudkowicz, Mamede De Carvalho, Angela Genge, Orla Hardiman, Carlayne E. Jackson, Noah Lechtzin, Hiroshi Mitsumoto, Vincenzo Silani, Jinsy A. Andrews, Dafeng Chen, Sarah Kulke, Stacy A. Rudnicki, Leonard H. van den Berg

Research output: Contribution to journalArticle

Abstract

Objective: To identify common practices of noninvasive ventilation (NIV) use among ALS specialists and how they follow respiratory status in their patients. Methods: A 25-item questionnaire on NIV indications/initiation was sent via SurveyMonkey® to ALS specialists identified through membership in NEALS (114 sites in the US) and ENCALS (39 sites in Europe). Descriptive statistics and Cochran–Mantel–Haenszel test for general association were performed. Results: In their initial evaluation, US and European specialists (n = 186) use upright forced vital capacity (FVC) most (92.8% vs 91.1%; p = 0.752). Upright FVC results are most important for US respondents when deciding to prescribe NIV; European respondents consider symptoms of orthopnea and/or dyspnea as most important. European respondents use overnight pulse oximetry (69.8% vs 7.9%; p < 0.001) and arterial blood gas analyses (62.8% vs 3.2%; p < 0.001) more than US respondents. Insurance regulations/national health care coverage impact NIV initiation more in the US than in Europe (70.0% vs 47.5%; p = 0.025). When asked if insurance/other financial constraints affects when they prescribe NIV, more US respondents answered positively (77.2% vs 15.4%; p < 0.001). In patients with no respiratory symptoms, most US specialists (68.3%) initiated NIV at VC <50% predicted; European responses showed greater variability. Conclusions: Given the impact of NIV on respiratory function and the importance of respiratory function to quality of life and survival, understanding differences that influence NIV prescribing is critical. This information may inform future study design and identify areas warranting additional research to develop best practices for NIV implementation.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration
DOIs
StateAccepted/In press - Apr 16 2018

Fingerprint

Noninvasive Ventilation
Vital Capacity
Insurance
Surveys and Questionnaires
Blood Gas Analysis
Oximetry
Practice Guidelines
Dyspnea
Quality of Life
Delivery of Health Care
Survival

Keywords

  • Amyotrophic lateral sclerosis
  • noninvasive ventilation
  • respiratory function
  • vital capacity

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Heiman-Patterson, T. D., Cudkowicz, M. E., De Carvalho, M., Genge, A., Hardiman, O., Jackson, C. E., ... van den Berg, L. H. (Accepted/In press). Understanding the use of NIV in ALS: results of an international ALS specialist survey. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 1-11. https://doi.org/10.1080/21678421.2018.1457058

Understanding the use of NIV in ALS : results of an international ALS specialist survey. / Heiman-Patterson, Terry D.; Cudkowicz, Merit E.; De Carvalho, Mamede; Genge, Angela; Hardiman, Orla; Jackson, Carlayne E.; Lechtzin, Noah; Mitsumoto, Hiroshi; Silani, Vincenzo; Andrews, Jinsy A.; Chen, Dafeng; Kulke, Sarah; Rudnicki, Stacy A.; van den Berg, Leonard H.

In: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 16.04.2018, p. 1-11.

Research output: Contribution to journalArticle

Heiman-Patterson, TD, Cudkowicz, ME, De Carvalho, M, Genge, A, Hardiman, O, Jackson, CE, Lechtzin, N, Mitsumoto, H, Silani, V, Andrews, JA, Chen, D, Kulke, S, Rudnicki, SA & van den Berg, LH 2018, 'Understanding the use of NIV in ALS: results of an international ALS specialist survey', Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, pp. 1-11. https://doi.org/10.1080/21678421.2018.1457058
Heiman-Patterson, Terry D. ; Cudkowicz, Merit E. ; De Carvalho, Mamede ; Genge, Angela ; Hardiman, Orla ; Jackson, Carlayne E. ; Lechtzin, Noah ; Mitsumoto, Hiroshi ; Silani, Vincenzo ; Andrews, Jinsy A. ; Chen, Dafeng ; Kulke, Sarah ; Rudnicki, Stacy A. ; van den Berg, Leonard H. / Understanding the use of NIV in ALS : results of an international ALS specialist survey. In: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2018 ; pp. 1-11.
@article{19db91385d1145838728f5ff9bb06cad,
title = "Understanding the use of NIV in ALS: results of an international ALS specialist survey",
abstract = "Objective: To identify common practices of noninvasive ventilation (NIV) use among ALS specialists and how they follow respiratory status in their patients. Methods: A 25-item questionnaire on NIV indications/initiation was sent via SurveyMonkey{\circledR} to ALS specialists identified through membership in NEALS (114 sites in the US) and ENCALS (39 sites in Europe). Descriptive statistics and Cochran–Mantel–Haenszel test for general association were performed. Results: In their initial evaluation, US and European specialists (n = 186) use upright forced vital capacity (FVC) most (92.8{\%} vs 91.1{\%}; p = 0.752). Upright FVC results are most important for US respondents when deciding to prescribe NIV; European respondents consider symptoms of orthopnea and/or dyspnea as most important. European respondents use overnight pulse oximetry (69.8{\%} vs 7.9{\%}; p < 0.001) and arterial blood gas analyses (62.8{\%} vs 3.2{\%}; p < 0.001) more than US respondents. Insurance regulations/national health care coverage impact NIV initiation more in the US than in Europe (70.0{\%} vs 47.5{\%}; p = 0.025). When asked if insurance/other financial constraints affects when they prescribe NIV, more US respondents answered positively (77.2{\%} vs 15.4{\%}; p < 0.001). In patients with no respiratory symptoms, most US specialists (68.3{\%}) initiated NIV at VC <50{\%} predicted; European responses showed greater variability. Conclusions: Given the impact of NIV on respiratory function and the importance of respiratory function to quality of life and survival, understanding differences that influence NIV prescribing is critical. This information may inform future study design and identify areas warranting additional research to develop best practices for NIV implementation.",
keywords = "Amyotrophic lateral sclerosis, noninvasive ventilation, respiratory function, vital capacity",
author = "Heiman-Patterson, {Terry D.} and Cudkowicz, {Merit E.} and {De Carvalho}, Mamede and Angela Genge and Orla Hardiman and Jackson, {Carlayne E.} and Noah Lechtzin and Hiroshi Mitsumoto and Vincenzo Silani and Andrews, {Jinsy A.} and Dafeng Chen and Sarah Kulke and Rudnicki, {Stacy A.} and {van den Berg}, {Leonard H.}",
year = "2018",
month = "4",
day = "16",
doi = "10.1080/21678421.2018.1457058",
language = "English (US)",
pages = "1--11",
journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",
issn = "2167-8421",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Understanding the use of NIV in ALS

T2 - results of an international ALS specialist survey

AU - Heiman-Patterson, Terry D.

AU - Cudkowicz, Merit E.

AU - De Carvalho, Mamede

AU - Genge, Angela

AU - Hardiman, Orla

AU - Jackson, Carlayne E.

AU - Lechtzin, Noah

AU - Mitsumoto, Hiroshi

AU - Silani, Vincenzo

AU - Andrews, Jinsy A.

AU - Chen, Dafeng

AU - Kulke, Sarah

AU - Rudnicki, Stacy A.

AU - van den Berg, Leonard H.

PY - 2018/4/16

Y1 - 2018/4/16

N2 - Objective: To identify common practices of noninvasive ventilation (NIV) use among ALS specialists and how they follow respiratory status in their patients. Methods: A 25-item questionnaire on NIV indications/initiation was sent via SurveyMonkey® to ALS specialists identified through membership in NEALS (114 sites in the US) and ENCALS (39 sites in Europe). Descriptive statistics and Cochran–Mantel–Haenszel test for general association were performed. Results: In their initial evaluation, US and European specialists (n = 186) use upright forced vital capacity (FVC) most (92.8% vs 91.1%; p = 0.752). Upright FVC results are most important for US respondents when deciding to prescribe NIV; European respondents consider symptoms of orthopnea and/or dyspnea as most important. European respondents use overnight pulse oximetry (69.8% vs 7.9%; p < 0.001) and arterial blood gas analyses (62.8% vs 3.2%; p < 0.001) more than US respondents. Insurance regulations/national health care coverage impact NIV initiation more in the US than in Europe (70.0% vs 47.5%; p = 0.025). When asked if insurance/other financial constraints affects when they prescribe NIV, more US respondents answered positively (77.2% vs 15.4%; p < 0.001). In patients with no respiratory symptoms, most US specialists (68.3%) initiated NIV at VC <50% predicted; European responses showed greater variability. Conclusions: Given the impact of NIV on respiratory function and the importance of respiratory function to quality of life and survival, understanding differences that influence NIV prescribing is critical. This information may inform future study design and identify areas warranting additional research to develop best practices for NIV implementation.

AB - Objective: To identify common practices of noninvasive ventilation (NIV) use among ALS specialists and how they follow respiratory status in their patients. Methods: A 25-item questionnaire on NIV indications/initiation was sent via SurveyMonkey® to ALS specialists identified through membership in NEALS (114 sites in the US) and ENCALS (39 sites in Europe). Descriptive statistics and Cochran–Mantel–Haenszel test for general association were performed. Results: In their initial evaluation, US and European specialists (n = 186) use upright forced vital capacity (FVC) most (92.8% vs 91.1%; p = 0.752). Upright FVC results are most important for US respondents when deciding to prescribe NIV; European respondents consider symptoms of orthopnea and/or dyspnea as most important. European respondents use overnight pulse oximetry (69.8% vs 7.9%; p < 0.001) and arterial blood gas analyses (62.8% vs 3.2%; p < 0.001) more than US respondents. Insurance regulations/national health care coverage impact NIV initiation more in the US than in Europe (70.0% vs 47.5%; p = 0.025). When asked if insurance/other financial constraints affects when they prescribe NIV, more US respondents answered positively (77.2% vs 15.4%; p < 0.001). In patients with no respiratory symptoms, most US specialists (68.3%) initiated NIV at VC <50% predicted; European responses showed greater variability. Conclusions: Given the impact of NIV on respiratory function and the importance of respiratory function to quality of life and survival, understanding differences that influence NIV prescribing is critical. This information may inform future study design and identify areas warranting additional research to develop best practices for NIV implementation.

KW - Amyotrophic lateral sclerosis

KW - noninvasive ventilation

KW - respiratory function

KW - vital capacity

UR - http://www.scopus.com/inward/record.url?scp=85045438804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045438804&partnerID=8YFLogxK

U2 - 10.1080/21678421.2018.1457058

DO - 10.1080/21678421.2018.1457058

M3 - Article

C2 - 29661084

AN - SCOPUS:85045438804

SP - 1

EP - 11

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

SN - 2167-8421

ER -